SALT LAKE CITY, UT--(Marketwired - March 03, 2016) - ReNovo Biotech, Inc. (ReNovo), a cellular, tissue and regenerative medicine company, today announced an exclusive partnership agreement with Salt Lake City based Nexus CMF to distribute ReNovo's allograft tissue products to craniomaxillofacial surgeons in the United States.
"Nexus CMF is committed to providing a versatile array of treatment solutions that enable CMF healthcare providers and health systems opportunities to improve overall patient outcomes," said Jared Crocker, Nexus CMF's President, "These amniotic derived products are unique in their quality and content. Nexus CMF is excited to provide our surgeon customers with this singular and minimally invasive alternative for their patients."
Eric Olson, ReNovo Biotech's CEO added, "Nexus CMF is a great partner for the ReNovo Biotech brand. They have the scale, infrastructure, reputation, clinical experience and complementary product portfolio to make ReNovo Biotech's products a market leader in the United States. We are pleased that Nexus CMF recognized the quality, innovation and need of our products."
ReNovo Biotech is focused on the development, processing and distribution of innovative allograft tissues, stem cells and biomaterials for the treatment of serious and debilitating diseases. The company develops and acquires technologies that incorporate the use of genome sequencing with proprietary tissue/stem cell recovery to ensure the highest quality treatment options for its surgeon customers and their patients.
Nexus CMF is a medical device company specializing in treatments for temporomandibular joint disorders. In addition to the newly launched allograft tissue products, the company offers a proprietary TMJ arthroscopy system and the only partial TMJ prosthesis approved by the FDA. It is also the only company in the United States to manufacture both stock and patient-specific TMJ prostheses.
The distribution agreement may be expanded with additional products and territories in the future. The terms of the agreement were not disclosed.
ReNovo Biotech recently announced the signing of a "Letter of Intent" to be acquired by Predictive Technology Group, Inc. (OTC PINK: PRED). This pending acquisition will in no way interfere with this partnership agreement with Nexus CMF.
For further information contact Daniel Borders, Borders Consulting Services, #407-520-4515, info@bordersconsultingservices.com, www.bordersconsultingservices.com and/or Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com.